Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
Go back to Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.71 -1.81 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $118.52 | 52 Week High | $118.49 | |||
| Open | $118.53 | 52 Week Low | $55.00 | |||
| Day High | $118.93 | P/E | N/A | |||
| Day Low | $115.21 | EPS | $-0.56 | |||
| Volume | 1,643,981 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1188.58 -28.37 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1216.95 | 52 Week High | $88.16 | |||
| Open | $1210.31 | 52 Week Low | $67.88 | |||
| Day High | $1212.96 | P/E | 275.13 | |||
| Day Low | $1178.32 | EPS | $4.32 | |||
| Volume | 2,009,850 | |||||
